product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-HER3/ErbB3 (Tyr1289) (21D3) Rabbit mAb
catalog :
4791S
quantity :
100 ul
price :
274 USD
clonality :
monoclonal
host :
rabbit
antigen modification :
phosphorylated
reactivity :
human, mouse, rat, dog
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section
more info or order :
Cell Signaling Technology product webpage
citations: 26
Published Application/Species/DilutionReference
  • western blot; human; fig 1
Cao K, Gong H, Qiu Z, Wen Q, Zhang B, Tang T, et al. Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells. Tumour Biol. 2016;: pubmed
  • western blot; human; fig 1
Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed publisher
  • immunohistochemistry - paraffin section; mouse; fig 6
Mancini M, Lien E, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016;7:17301-13 pubmed publisher
  • western blot; human; fig 2
Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomić T, et al. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget. 2016;7:433-45 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100
Creedon H, Balderstone L, Muir M, Balla J, Gómez-Cuadrado L, Tracey N, et al. Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech. 2016;9:131-40 pubmed publisher
  • western blot; human; fig 1
  • immunocytochemistry; human; fig s3
Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed publisher
  • western blot; human; fig 1
Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5:e211 pubmed publisher
  • western blot; human
Rios-Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, et al. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther. 2015;14:1637-49 pubmed publisher
  • western blot; human; fig 2
Momeny M, Saunus J, Marturana F, McCart Reed A, Black D, Sala G, et al. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015;6:3932-46 pubmed
  • western blot; human
Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher
  • immunohistochemistry; human; 1:30
Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed
  • western blot; human
Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher
  • western blot; human
Ni M, Chen Y, Fei T, Li D, Lim E, Liu X, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013;27:734-48 pubmed publisher
  • western blot; human
Lindberg K, Helguero L, Omoto Y, Gustafsson J, Haldosén L. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13:R43 pubmed publisher
Blair B, Wu X, Zahari M, Mohseni M, Cidado J, Wong H, et al. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics. 2015;15:318-26 pubmed publisher
Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, et al. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014;21:S490-6 pubmed publisher
Paulson A, Linklater E, Berghuis B, App C, Oostendorp L, Paulson J, et al. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res. 2013;11:1112-21 pubmed publisher
Sak M, Szymanska M, Bertelsen V, Hasmann M, Madshus I, Stang E. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis. 2013;34:2031-8 pubmed publisher
Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 2012;18:1663-71 pubmed publisher
Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev I, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 2012;181:1034-43 pubmed publisher
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012;11:2149-57 pubmed publisher
Weigelt B, Lo A, Park C, Gray J, Bissell M. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010;122:35-43 pubmed publisher
Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 2012;30:1352-60 pubmed publisher
Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012;18:3592-602 pubmed publisher
Frogne T, Laenkholm A, Lyng M, Henriksen K, Lykkesfeldt A. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11:R11 pubmed publisher
Sergina N, Rausch M, Wang D, Blair J, Hann B, Shokat K, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437-41 pubmed
product information
SKU :
4791S
Product-Name :
Phospho-HER3/ErbB3 (Tyr1289) (21D3) Rabbit mAb
Size :
100 ul
Price-(USD) :
274 USD
Species-x-Reactivity :
H, (M, R, Dg)
Applications :
Immunohistochemistry (Paraffin)
Product-Category :
RTK
Shipping-Temp :
COLD
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
185
Host :
Rabbit
Target :
HER3/ErbB3 (Tyr1289) phosphate
Primary-Protein :
HER3
Alt-Names :
ERBB3,ErbB-3,HER3,LCCS2,MDA-BF-1,MGC88033,Proto-oncogene-like protein c-ErbB-3,Receptor tyrosine-protein kinase erbB-3,Tyrosine kinase-type cell surface receptor HER3,c-erbB-3,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3,v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3,v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.